Concepedia

Jeremy H. Toyn

JH

Statistics

Publications

44

Citations

2.2K

H-Index

25

Active since

1988

Affiliations

Bristol-Myers Squibb (United States)(Current)

DuPont (United States)

The Francis Crick Institute

Wilmington University

Pfizer (United States)

Jeremy H. Toyn is an author at Bristol-Myers Squibb (United States) specializing in medicine, natural sciences, and biochemistry.

ORCID

Top concepts

Publications per year

1988–2019

44

Publications

44

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

Kevin W. Gillman, John E. Starrett, Michael F. Parker et al. · ACS Medicinal Chemistry Letters · 2010 · 183 citations

, , +19

Saccharomyces cerevisiae Is Capable of de Novo Pantothenic Acid Biosynthesis Involving a Novel Pathway of β-Alanine Production from Spermine

W. Hunter White, Paul L. Gunyuzlu, Jeremy H. Toyn · Journal of Biological Chemistry · 2001 · 175 citations · Full text

P40SDB25, a putative CDK inhibitor, has a role in the M/G1 transition in Saccharomyces cerevisiae.

Joseph Donovan, Jeremy H. Toyn, A. L. Johnson et al. · Genes & Development · 1994 · 141 citations · Full text

, , +21

A counterselection for the tryptophan pathway in yeast: 5-fluoroanthranilic acid resistance

Jeremy H. Toyn, Paul L. Gunyuzlu, W. Hunter White et al. · Yeast · 2000 · 130 citations

, , +19

The Dbf2 and Dbf20 protein kinases of budding yeast are activated after the metaphase to anaphase cell cycle transition.

Jeremy H. Toyn, Leland H. Johnston · The EMBO Journal · 1994 · 129 citations · Full text

, , +11

Rows per page

1–5 of 44